Agios Pharmaceuticals (AGIO) Accumulated Depreciation & Amortization (2016 - 2025)
Agios Pharmaceuticals (AGIO) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $56.5 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Accumulated Depreciation & Amortization rose 8.17% year-over-year to $56.5 million, compared with a TTM value of $56.5 million through Dec 2024, up 8.17%, and an annual FY2024 reading of $56.5 million, up 8.17% over the prior year.
- Accumulated Depreciation & Amortization was $56.5 million for Q4 2024 at Agios Pharmaceuticals, up from $52.2 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $56.5 million in Q4 2024 and bottomed at $41.4 million in Q4 2020.
- Average Accumulated Depreciation & Amortization over 5 years is $49.0 million, with a median of $50.1 million recorded in 2022.
- The sharpest move saw Accumulated Depreciation & Amortization soared 411.35% in 2020, then rose 4.31% in 2023.
- Year by year, Accumulated Depreciation & Amortization stood at $41.4 million in 2020, then grew by 8.76% to $45.0 million in 2021, then rose by 11.33% to $50.1 million in 2022, then increased by 4.31% to $52.2 million in 2023, then increased by 8.17% to $56.5 million in 2024.
- Business Quant data shows Accumulated Depreciation & Amortization for AGIO at $56.5 million in Q4 2024, $52.2 million in Q4 2023, and $50.1 million in Q4 2022.